Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopoly on all the good ideas," Doustdar tells Bloomberg Television. "When there is a gap, strategically or scientifically, we're looking outside to see how we can fill the gaps." (Source: Bloomberg)
Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopoly on all the good ideas," Doustdar tells Bloomberg Television. "When there is a gap, strategically or scientifically, we're looking outside to see how we can fill the gaps." (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/5fc211876db0db065e69316385ebeac11a69f22c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novo Still Has Work to Do to Build Investor Confidence, CEO Says"></iframe>